专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007048026A2 CGRP PEPTIDE ANTAGONISTS AND CONJUGATES 审中-公开
标题翻译： CGRP肽拮抗剂和共轭物
公开(公告)号：WO2007048026A2
公开(公告)日：2007-04-26
申请号：PCT/US2006/041220
申请日：2006-10-20
申请人： AMGEN INC. , GEGG, Colin V., Jr. , MIRANDA, Leslie P. , WALKER, Kenneth W. , JOHNSON, Eileen J. , HOLDER, Jerry Ryan , WRIGHT, Marie E. , D'AMICO, Derin C.
发明人： GEGG, Colin V., Jr. , MIRANDA, Leslie P. , WALKER, Kenneth W. , JOHNSON, Eileen J. , HOLDER, Jerry Ryan , WRIGHT, Marie E. , D'AMICO, Derin C.
CPC分类号： A61K38/225 , C07K14/57527
摘要： Disclosed is a composition of matter that involves a CGRP peptide antagonist. A pharmaceutical composition is disclosed that comprises the composition of matter and a pharmaceutically acceptable carrier, which can be configured for administration to a patient. Also disclosed is a method of producing the composition of matter. Methods of treating, preventing or mitigating migraine, are also disclosed.
摘要翻译：公开了涉及CGRP肽拮抗剂的物质组合物。公开了药物组合物，其包含可配置用于施用于患者的物质组合物和药学上可接受的载体。还公开了生产物质组合物的方法。还公开了治疗，预防或缓解偏头痛的方法。

2. 发明申请

WO2010042747A2 FGF21 MUTANTS AND USES THEREOF 审中-公开
公开(公告)号：WO2010042747A2
公开(公告)日：2010-04-15
申请号：PCT/US2009/060045
申请日：2009-10-08
申请人： AMGEN INC. , WALKER, Kenneth W. , GEGG, Colin, V., Jr. , HECHT, Randy I. , BELOUSKI, Edward J. , LI, Yue-Sheng , MICHAELS, Mark L. , XU, Jing , ELLISON, Murielle M.
发明人： WALKER, Kenneth W. , GEGG, Colin, V., Jr. , HECHT, Randy I. , BELOUSKI, Edward J. , LI, Yue-Sheng , MICHAELS, Mark L. , XU, Jing , ELLISON, Murielle M.
IPC分类号： C07K14/50 , A61K38/18
CPC分类号： C07K14/50 , A61K38/00 , A61K47/60
摘要： The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

3. 发明申请

WO2010108154A2 SELECTIVE AND POTENT PEPTIDE INHIBITORS OF KV1.3 审中-公开
标题翻译： KV1.3的选择和磷酸肽抑制剂
公开(公告)号：WO2010108154A2
公开(公告)日：2010-09-23
申请号：PCT/US2010/028061
申请日：2010-03-19
申请人： AMGEN INC. , SULLIVAN, John K. , MIRANDA, Leslie P. , GEGG, Colin V. , HU, Shaw-Fen Sylvia , BELOUSKI, Edward J. , MURRAY, Justin K. , NGUYEN, Hung , WALKER, Kenneth W. , ARORA, Taruna , JACOBSEN, Frederick W. , LI, Yue-Sheng , BOONE, Thomas C.
发明人： SULLIVAN, John K. , MIRANDA, Leslie P. , GEGG, Colin V. , HU, Shaw-Fen Sylvia , BELOUSKI, Edward J. , MURRAY, Justin K. , NGUYEN, Hung , WALKER, Kenneth W. , ARORA, Taruna , JACOBSEN, Frederick W. , LI, Yue-Sheng , BOONE, Thomas C.
IPC分类号： A61K38/16
CPC分类号： C07K16/44 , A61K39/39591 , A61K47/6817 , A61K47/6843 , C07K14/43504 , C07K14/575 , C07K14/605 , C07K14/66 , C07K16/00 , C07K16/18 , C07K16/248 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30 , C07K2319/55
摘要： Disclosed are compositions of matter having an amino acid sequence of SEQ ID NO:4, or a pharmaceutically acceptable salt thereof, including embodiments comprising a toxin peptide analog related to ShK, HmK, and AETX-K and pharmaceutical compositions or medicaments containing them along with a pharmaceutically acceptable carrier. Some embodiments include a half-life extending moiety. Also disclosed are a method of preventing or mitigating a relapse of a symptom of multiple sclerosis and a method of treating an autoimmune disorder using the compositions.
摘要翻译：公开了具有SEQ ID NO：4的氨基酸序列或其药学上可接受的盐的物质组合物，包括包含与ShK，HmK和AETX-K相关的毒素肽类似物的实施方案，以及含有它们的药物组合物或药物以及药学上可接受的载体。一些实施方案包括半衰期延长部分。还公开了预防或减轻多发性硬化症状的复发的方法以及使用该组合物治疗自身免疫病症的方法。

4. 发明公开

EP2619226A2 CARRIER IMMUNOGLOBULINS AND USES THEREOF 有权转让
标题翻译： TRERGER-IMMUNGLOBULINE VERWENDUNGEN DAVON
公开(公告)号：EP2619226A2
公开(公告)日：2013-07-31
申请号：EP11763827.0
申请日：2011-09-22
申请人： Amgen Inc. , Walker, Kenneth W. , Arora, Taruna , Jacobsen, Frederick W.
发明人： WALKER, Kenneth W. , ARORA, Taruna , JACOBSEN, Frederick W.
IPC分类号： C07K16/00 , C07K16/18 , C07K16/28 , A61K39/395
CPC分类号： C07K16/2878 , A61K38/1767 , A61K47/6871 , A61K2039/6056 , C07K16/18 , C07K16/2866 , C07K16/2875 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C07K2319/30
摘要： Disclosed is an isolated immunoglobulin. Also disclosed are pharmaceutical compositions and medicaments comprising the immunoglobulin, isolated nucleic acid encoding it, vectors, host cells, useful in methods of making it. In some embodiments the immunoglobulin comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
摘要翻译：公开了一种分离的免疫球蛋白。还公开了包含免疫球蛋白，编码它的分离的核酸，载体，宿主细胞的药物组合物和药物，其用于制备它的方法。在一些实施方案中，免疫球蛋白包含与其缀合的1-24个药理活性化学部分，例如药理学活性多肽。

5. 发明申请

WO2012040518A2 CARRIER IMMUNOGLOBULINS AND USES THEREOF 审中-公开
标题翻译：载体免疫球蛋白及其用途
公开(公告)号：WO2012040518A2
公开(公告)日：2012-03-29
申请号：PCT/US2011/052841
申请日：2011-09-22
申请人： AMGEN INC. , WALKER, Kenneth W. , ARORA, Taruna , JACOBSEN, Frederick W.
发明人： WALKER, Kenneth W. , ARORA, Taruna , JACOBSEN, Frederick W.
IPC分类号： C07K16/00 , C07K16/18 , C07K16/28 , A61K39/395
CPC分类号： C07K16/2878 , A61K38/1767 , A61K47/6871 , A61K2039/6056 , C07K16/18 , C07K16/2866 , C07K16/2875 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C07K2319/30
摘要： Disclosed is an isolated immunoglobulin. Also disclosed are pharmaceutical compositions and medicaments comprising the immunoglobulin, isolated nucleic acid encoding it, vectors, host cells, useful in methods of making it. In some embodiments the immunoglobulin comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
摘要翻译：公开了一种分离的免疫球蛋白。还公开了包含免疫球蛋白，编码它的分离的核酸，载体，宿主细胞的药物组合物和药物，其用于制备它的方法。在一些实施方案中，免疫球蛋白包含与其结合的1-24个药理活性化学部分，例如药理学活性多肽。

6. 发明申请

WO2017106383A1 ANTI-TL1A/ANTI-TNF-ALPHA BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF 审中-公开
标题翻译：抗TL1A /抗TNF-α双特异性抗原结合蛋白及其用途
公开(公告)号：WO2017106383A1
公开(公告)日：2017-06-22
申请号：PCT/US2016/066722
申请日：2016-12-14
申请人： AMGEN INC.
发明人： HSU, Hailing , KANNAN, Gunasekaran , WALKER, Kenneth W. , HORTTER, Michelle , BELOUSKI, Edward J.
IPC分类号： C07K16/24
CPC分类号： C07K16/2875 , C07K16/241 , C07K2317/21 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/66 , C07K2317/76 , C07K2317/90 , C07K2319/00
摘要： The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-α. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-α. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-alpha antigen binding proteins, and pharmaceutical formulations thereof.
摘要翻译：本发明涉及结合TL1A的抗原结合蛋白，包括TL1A和TNF-α的双特异性抗原结合蛋白（例如抗体）。这样的双特异性抗体可以是四聚体免疫球蛋白形式，其中抗体的一个重链 - 轻链对针对TL1A而另一个针对TNF-α。双特异性抗原结合蛋白也可以包含在IgG-scFv融合物中，其中针对一种抗原的常规四聚体抗体与针对另一种抗原的一对单链Fv单元融合。双特异性抗原结合蛋白也可以包含在IgG-Fab融合物中，其中与一种抗原结合的Fab分子与针对另一种抗原的常规四聚体抗体的每种重链融合。本发明进一步涉及抗TL1A结合蛋白和抗TL1A /抗TNF-α抗原结合蛋白及其药物制剂的用途。

7. 发明申请

WO2007022070A3 MODIFIED FC MOLECULES 审中-公开
公开(公告)号：WO2007022070A3
公开(公告)日：2007-02-22
申请号：PCT/US2006/031609
申请日：2006-08-11
申请人： AMGEN INC.
发明人： GEGG, JR., Colin V. , WALKER, Kenneth W. , MIRANDA, Leslie P. , XIONG, Fei
IPC分类号： A61K47/48
摘要： Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them. A DNA encoding the inventive composition of matter, an expression vector containing the DNA, and a host cell containing the expression vector are also disclosed.

8. 发明申请

WO2018237095A1 METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING ANTAGONISTIC BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR)/GLP-1 RECEPTOR AGONIST FUSION PROTEINS 审中-公开
公开(公告)号：WO2018237095A1
公开(公告)日：2018-12-27
申请号：PCT/US2018/038634
申请日：2018-06-20
申请人： AMGEN INC.
发明人： WALKER, Kenneth W. , HOLDER, Jerry Ryan , LLOYD, David J. , LU, Shu-Chen , VENIANT-ELLISON, Murielle M. , STANISLAUS, Shanaka
IPC分类号： C07K16/28 , A61K38/26
摘要： Method of treating metabolic diseases and disorders using a composition comprising a GLP-l/GIPR antigen binding protein fusion protein are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises the C-terminus of a GLP-1 analog fused to the N-terminus of the light chain variable or heavy chain variable region of an antibody or functional fragment thereof that binds GIPR, optionally with a linker in between.

9. 发明申请

WO2006116156A2 TOXIN PEPTIDE THERAPEUTIC AGENTS 审中-公开
标题翻译：毒素代谢治疗药物
公开(公告)号：WO2006116156A2
公开(公告)日：2006-11-02
申请号：PCT/US2006/015199
申请日：2006-04-18
申请人： AMGEN INC.
发明人： SULLIVAN, John K. , MCGIVERN, Joseph G. , MIRANDA, Leslie P. , NGUYEN, Hung Q. , WALKER, Kenneth W. , HU, Shaw-Fen Sylvia , GEGG JR., Colin V. , MCDONOUGH, Stefan I.
IPC分类号： C12N15/62 , A61K47/48 , C12N15/12
CPC分类号： A61K47/48215 , A61K38/00 , A61K47/60 , C07K14/43504 , C07K2319/30 , C07K2319/55
摘要： Disclosed is a composition of matter of the formula (I) (X 1 ) a -(F 1 ) d -(X 2 ) b -(F 2 ) e -(X 3 ) c and multimers thereof, in which F1 and F2 are half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1; X 1 , X 2 , and X 3 are each independently -(L) f -P-(L) g -, and f and g are each independently 0 or 1; P is a toxin peptide of no more than about 80 amino acid residues in length, comprising at least two intrapeptide disulfide bonds; L is an optional linker; and a, b, and c are each independently 0 or 1, provided that at least one of a, b and c is 1. Linkage to the half-life extending moiety or moieties increases the in vivo half-life of the toxin peptide, which otherwise would be quickly degraded. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are a DNA encoding the inventive composition of matter, an expression vector comprising the DNA, and a host cell comprising the expression vector. Methods of treating an autoimmune disorder, such as, but not limited to, multiple sclerosis, type 1 diabetes, obesity, psoriasis, inflammatory bowel disease, contact-mediated dermatitis, rheumatoid arthritis, psoriatic arthritis, transplant rejection, graft-versus-host disease, and lupus and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.
摘要翻译：公开了式（I）（X 1）的物质组合物（X 1） > - （X ^{2 ）_{b'/ SUB> - （F ^{2 ）_{ë - （X ³}}}}

10. 发明申请

WO2017106383A4 ANTI-TL1A/ANTI-TNF-ALPHA BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF 审中-公开
公开(公告)号：WO2017106383A4
公开(公告)日：2017-06-22
申请号：PCT/US2016/066722
申请日：2016-12-14
申请人： AMGEN INC.
发明人： HSU, Hailing , KANNAN, Gunasekaran , WALKER, Kenneth W. , HORTTER, Michelle , BELOUSKI, Edward J.
IPC分类号： C07K16/24
摘要： The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-α. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-α. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-alpha antigen binding proteins, and pharmaceutical formulations thereof.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式